Bicara Therapeutics Common Stock Accounts Payable

Bicara Therapeutics Common Stock's accounts payable stands at $6.2M as of March 2026. That compares with $2.4M in the prior-year period — up 162.8% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Bicara Therapeutics Common Stock reported $6.2M in accounts payable versus $2.4M a year earlier — a 162.8% year-over-year increase. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $2.4M in the prior-year period — up 162.8% year over year. Sustained growth in accounts payable can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Bicara Therapeutics Common Stock's accounts payable evolved across reporting periods, while the comparison chart places BCAX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, accounts payable is commonly used to spot outliers. Bicara Therapeutics Common Stock's reading of $6.2M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.